Tasly Biopharmaceutical Technology

Tasly Biopharmaceuticals is a commercial-stage Chinese biotechnology company and a subsidiary of Tasly Pharmaceutical Group. The company focuses on the development of innovative biologics for cardiovascular diseases, oncology, and metabolic disorders. Its lead product, Pulexian (recombinant human prourokinase), is an approved thrombolytic agent for acute myocardial infarction in China. Tasly Biopharmaceuticals operates integrated platforms for R&D and large-scale GMP manufacturing of recombinant proteins and monoclonal antibodies. The company's pipeline includes several late-stage candidates targeting ischemic stroke, hyperlipidemia, and various cancers.